| 讲座 |
|
|
|
|
| 细胞药物的临床应用——细胞药物连载之五 |
| 王佃亮 |
| 中国人民解放军火箭军总医院药学部组织工程与再生医学实验室 北京 100088 |
|
| The Clinical Application of Cell Drug |
| WANG Dian-liang |
| Tissue Engineering and Regenerative Medicine Laboratory, The General Hospital of The PLA Rocket Force, Beijing 100088, China |
| [1] Plaza Reyes A, Petrus-Reurer S, Antonsson L, et al. Xeno-free and defined human embryonic stem cell-derived retinal pigment epithelial cells functionally integrate in a large-eyed preclinical model.Stem Cell Reports,2016,6(1):9-17.
[2] Peng Y.The patentability of human embryonic stem cell technology in China. Nat Biotechnol,2016,34(1):37-39.
[3] Schwartz S D, Hubschman J P, Heilwell G. Embryonic stem cell trials for macular degeneration:a preliminary report. Lancet,2012,379(9817):713-720.
[4] Jiang P C, Xiong W P, Wang G. A clinical trial report of autologous bone marrow-derived mesenchymal stem cell transplantation in patients with spinal cord injury. Exp Ther Med, 2013, 6(1):140-146.
[5] Honmou O, HoukinK, Matsunaga T. Intravenous administration of auto serum-expanded autologous mesenchymal stem cells in stroke. Brain, 2011,134(Pt 6):1790-1807.
[6] Liu J, Han D, Wang Z. Clinical analysis of the treatment of spinal cord injury with umbilical cord mesenchymal stem cells. Cytotherapy,2013,15(2):185-191.
[7] Li Z M, Zhang Z T, Guo C J. Autologous bone marrow mononuclear cell implantation for intracerebral hemorrhage-a prospective clinical observation. Clin Neurol Neurosurg, 2013,115(1):72-76.
[8] Wang L, Wang L, Cong X. Human umbilical cord mesenchymal stem cell therapy for patients with active rheumatoid arthritis:safety and efficacy. Stem Cells and Development,2013, 22(24):3192-3202.
[9] Clifford D M, Fisher S A, Brunskill S J.Stem cell treatment for acute myocardial infarction. Cochrane Database Syst Rev, 2012,2:Cd006536.
[10] Hare J M, Fishman J E, Gerstenblith G.Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy:the POSEIDON randomized trial.JAMA, 2012,308(22):2369-2379.
[11] Makkar R R, Smith R R, Cheng K. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS):a prospective, randomised phase 1 trial. The Lancet,2012,379(9819):895-904.
[12] Malliaras K, Makkar R R, Smith R R. Intracoronary cardiosphere-derived cells after myocardial infarction evidence of therapeutic regeneration in the final 1-year results of the CADUCEUS trial (Cardiosphere-derived autologous stem cells to reverse ventricular dysfunction). Journal of the American College of Cardiology,2014, 63(2):110-122.
[13] Vrtovec B, PoglajenG, Lezaic L. Effects of intracoronary CD34+ stem cell transplantation in nonischemic dilated cardiomyopathy patients:5-year follow-up. Circ Res,2013, 112(1):165-173.
[14] Anasetti C, Logan B R, Lee S J. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med, 2012,367(16):1487-1496.
[15] Li X H, Gao C J, Da W M. Reduced intensity conditioning, combined transplantation of haploidentical hematopoietic stem cells and mesenchymal stem cells in patients with severe aplastic anemia. PLoS One, 2014,,9(3):e89666.
[16] Wei F Q, Sun W, Wong T S, et al. Eliciting cytotoxic T lymphocytes against human laryngeal cancer-derived antigens:evaluation of dendritic cells pulsed with a heat-treated tumor lysate and other antigen-loading strategies for dendritic-cell-based vaccination.J Exp Clin Cancer Res, 2016,35(1):18. |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
